| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H21F2N3O |
| Molar mass | 345.394 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tedalinab (GRC-10693) is a drug developed byGlenmark Pharmaceuticals for the treatment ofosteoarthritis andneuropathic pain, which acts as a potent and selectivecannabinoidCB2receptoragonist. It has a very high selectivity of 4700x for CB2 over the relatedCB1 receptor, has good oral bioavailability and has shown promising safety results and effectiveanalgesic andantiinflammatory actions in earlyclinical trials.[1] Many related compounds are known, most of which also show high CB2 selectivity.[2]
Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |